Antihypertensive efficacy and safety of a standardized herbal medicinal product of Hibiscus sabdariffa and Olea europaea extracts (NW Roselle): A phase-II, randomized, double-blind, captopril-controlled clinical trial

Elkafrawy N 1 , Younes K 2 , Naguib A 3 , Badr H 4 , Kamal Zewain S 4 , Kamel M 4 Show all authors , Raoof GFA 5 , M El-Desoky A 6 , Mohamed S 7

Affiliations 

  • 1 Internal Medicine and Diabetology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
  • 2 Internal Medicine Department, Medical Division, National Research Centre, Giza, Egypt
  • 3 Faculty of Medicine, Cardiology and Angiology, Alexandria University, Alexandria, Egypt
  • 4 Faculty of Medicine, Internal Medicine, Diabetes and Endocrinology, Menoufia University, Menoufia, Egypt
  • 5 Pharmacognosy Department, Pharmaceutical and Drug Research Industries Division, National Research Centre, Giza, Egypt
  • 6 Molecular Biology, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Sadat City, Egypt
  • 7 School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Malaysia
Phytother Res, 2020 Dec;34(12):3379-3387.
PMID: 32725873 DOI: 10.1002/ptr.6792

Abstract

Hypertension is a public health concern that needs immediate attention upon diagnosis. The demand for natural alternatives is on the rise; Hibiscus sabdariffa and Olea europaea are traditionally used for hypertension management in Egypt. In this study, we aimed to investigate the antihypertensive efficacy and safety of two doses of an herbal product of Hibiscus sabdariffa calyxes and Olea europaea leaves (NW Roselle) in Egyptian patients with grade 1 essential hypertension. We equally randomized 134 patients to receive captopril 25 mg, low-dose NW Roselle, or high-dose NW Roselle BID for 8 weeks. No significant decrease was found in systolic blood pressure or diastolic blood pressure when we compared low-dose NW Roselle and high-dose NW Roselle to captopril (p > .05). In all groups, mean reduction in BP at 8 weeks was significant; 16.4/9.9 mmHg (p

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications